Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangyi Meng

Showing results (41-50 of 135) with videos related to

Pageof 14
Sort By:
American Journal of Alzheimer'S Disease and Other Dementias|December 7, 2010
Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's diseaseGeorge T Grossberg, Frederick A Schmitt, Xiangyi Meng, et al.
Dermatology and Therapy|August 31, 2016
Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 StudiesLeon Kircik, Joseph Fowler, Jonathan Weiss, et al.
ACS Applied Materials & Interfaces|January 10, 2019
Achieving High Doping Concentration by Dopant Vapor Deposition in Organic Solar CellsHan Yan, Yabing Tang, Xiangyi Meng, et al.
Contemporary Clinical Trials|December 30, 2014
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMSXiangyi Meng, Peter S Chin, Ron Hashmonay, et al.
Current Medical Research and Opinion|September 11, 2010
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's diseaseMartin R Farlow, George Grossberg, Serge Gauthier, et al.
Carbohydrate Polymers|March 26, 2021
Development and characterization of zein edible films incorporated with catechin/β-cyclodextrin inclusion complex nanoparticlesLongwei Jiang, Fuguo Jia, Yanlong Han, et al.
Dermatology and Therapy|September 1, 2016
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 StudiesAlan Menter, Jennifer C Cather, Michael Jarratt, et al.
CNS Spectrums|January 15, 2013
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trialAndrew J Cutler, Amir H Kalali, Greg W Mattingly, et al.
International Journal of Geriatric Psychiatry|August 12, 2009
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)Jason T Olin, Vinod Bhatnagar, Patricio Reyes, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 17, 2020
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosisDevon S Conway, Nicolas R Thompson, Xiangyi Meng, et al.
Pageof 14

Showing results (41-50 of 135) with videos related to

Sort By:
Pageof 14
American Journal of Alzheimer'S Disease and Other Dementias|December 7, 2010
Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's diseaseGeorge T Grossberg, Frederick A Schmitt, Xiangyi Meng, et al.
Dermatology and Therapy|August 31, 2016
Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 StudiesLeon Kircik, Joseph Fowler, Jonathan Weiss, et al.
ACS Applied Materials & Interfaces|January 10, 2019
Achieving High Doping Concentration by Dopant Vapor Deposition in Organic Solar CellsHan Yan, Yabing Tang, Xiangyi Meng, et al.
Contemporary Clinical Trials|December 30, 2014
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMSXiangyi Meng, Peter S Chin, Ron Hashmonay, et al.
Current Medical Research and Opinion|September 11, 2010
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's diseaseMartin R Farlow, George Grossberg, Serge Gauthier, et al.
Carbohydrate Polymers|March 26, 2021
Development and characterization of zein edible films incorporated with catechin/β-cyclodextrin inclusion complex nanoparticlesLongwei Jiang, Fuguo Jia, Yanlong Han, et al.
Dermatology and Therapy|September 1, 2016
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 StudiesAlan Menter, Jennifer C Cather, Michael Jarratt, et al.
CNS Spectrums|January 15, 2013
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trialAndrew J Cutler, Amir H Kalali, Greg W Mattingly, et al.
International Journal of Geriatric Psychiatry|August 12, 2009
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)Jason T Olin, Vinod Bhatnagar, Patricio Reyes, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 17, 2020
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosisDevon S Conway, Nicolas R Thompson, Xiangyi Meng, et al.
Pageof 14